stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Return on invested capital
Travere Therapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −54.1%, down 16.2 percentage points from fiscal 2025 (−37.8%). Over the past ten years it has ranged from −2,161.7% (fiscal 2023) to 0.00% (fiscal 2024); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −37.8% | (37.84) |
| FY2024 | 0.00% | 2,161.70 |
| FY2023 | −2,161.7% | (2,161.70) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 169.48 |
| FY2020 | −169.5% | 142.33 |
| FY2019 | −311.8% | (192.14) |
| FY2018 | −119.7% | (30.21) |
| FY2017 | −89.5% | (51.68) |
| FY2016 | −37.8% | (9.99) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| CRSP CRISPR Therapeutics AG compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −9.54% |
| DNTH Dianthus Therapeutics, Inc. compare | −36.6% |
| TVTX Travere Therapeutics, Inc. | −54.1% |
| ERAS Erasca, Inc. compare | −203.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement